Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5718, Formulation A · 1 trial · 1 indication
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
To evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation used in the ongoing Phase 2a clinical study (Reference treatment), in healthy volunteers
| Arm | Type | Description |
|---|---|---|
| AZD5718 tablet, Treatment A | EXPERIMENTAL | Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. |
| AZD5718 tablet, Treatment B | EXPERIMENTAL | Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. |
| AZD5718 tablet, Treatment C | EXPERIMENTAL | Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. |
| AZD5718 tablet, Treatment D | EXPERIMENTAL | Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. |
| AZD5718 film-coated tablet | ACTIVE_COMPARATOR | Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. |
| Name | Type | Description |
|---|---|---|
| AZD5718 tablet, Formulation A | DRUG | Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours. |
| AZD5718 tablet, Formulation B | DRUG | Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours. |
| AZD5718 tablet, Formulation C | DRUG | Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours. |
| AZD5718 tablet, Formulation D | DRUG | Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours. |
| AZD5718 film-coated tablet, Reference treatment | DRUG | Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours. |
Inclusion Criteria: For inclusion in the study volunteers should fulfill the following criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male or female volunteers aged 18 to 55 years (inclusive at screening) with suitable veins fo...
AZD5718 is an investigational small molecule being developed by AstraZeneca for cardiovascular and kidney conditions, including coronary artery disease, chronic kidney disease, and cardiovascular disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD5718 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is in early-stage clinical development, with Phase 1 trials completed.
AZD5718 is in Phase 1 clinical development. All completed trials for the drug are Phase 1 studies, and it remains investigational, meaning it has not received regulatory approval for any indication.
AZD5718 has been studied in several completed Phase 1 trials, including NCT03400488, which assessed safety and tolerability in healthy Japanese men, and NCT03948451, a mass balance study. Other trials include NCT04210388, evaluating drug levels and safety of different formulations, and NCT04492709, a drug interaction study with midazolam.
Yes, all completed clinical trials for AZD5718 have enrolled healthy volunteers. These include studies in healthy Japanese men, healthy male volunteers in the United Kingdom, and trials open to all sexes, with the goal of assessing safety, pharmacokinetics, and drug interactions.